Last reviewed · How we verify

Copenhagen Studies on Asthma in Childhood — Portfolio Competitive Intelligence Brief

Copenhagen Studies on Asthma in Childhood pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ActivBiotics Pharma, LLC · 1 shared drug class
  2. Ain Shams Maternity Hospital · 1 shared drug class
  3. Baqiyatallah Medical Sciences University · 1 shared drug class
  4. Celltrion · 1 shared drug class
  5. Grünenthal GmbH · 1 shared drug class
  6. Lihir Medical Centre · 1 shared drug class
  7. London School of Hygiene and Tropical Medicine · 1 shared drug class
  8. Abbott · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Copenhagen Studies on Asthma in Childhood:

Cite this brief

Drug Landscape (2026). Copenhagen Studies on Asthma in Childhood — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/copenhagen-studies-on-asthma-in-childhood. Accessed 2026-05-17.

Related